Completion of the Pivotal Phase 3 Trial for Olanzapine LAI in Schizophrenia Conducted by Teva Pharmaceuticals
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 10 2025
0mins
Source: Yahoo Finance
Medincell's Milestone Payment: Medincell will receive a $5 million milestone payment from Teva following the completion of the SOLARIS study, which is crucial for the development of a long-acting injectable formulation of olanzapine for schizophrenia patients.
Regulatory Submission Plans: The Chief Medical Officer at Medincell emphasized that their partner is progressing towards regulatory submission in the US, demonstrating a commitment to meet an important healthcare need.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
